Efficacy findings from the phase 2 AGAVE-201 support the use of axatilimab, which was approved by the FDA for recurrent or ...

The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to ...

The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Kawasaki disease is a ...

Dr. Meng and his colleagues found that patients in the aumolertinib arm had a longer progression-free survival than patients randomized to the placebo group. Median PFS by BICR was 30.4 months for ...

Scientists found that the juice reduced levels of creatinine phosphokinase (CPK) and lactate dehydrogenase (LDH), markers of exercise-induced muscle damage. These compounds returned to almost ...

1 Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, United States 2 Division of Gastroenterology, Hepatology and Nutrition, Department of Internal ...

The most frequently reported AE from months 0 to 3 was upper respiratory tract infection, followed by blood creatine phosphokinase increased, hyperlipidaemia, diarrhoea and abdominal discomfort. From ...

Nat Clin Pract Nephrol. 2006;2(3):136-148. Hypophosphatemia associated with primary hyperparathyroidism is usually of moderate severity; increased urinary phosphate excretion is balanced by ...